Saturday 17 October 2026
Export LFWD’s income statement to Excel — free account
Lifeward Ltd.
LFWD Healthcare Medical Devices
Lifeward Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $22.0 million, down 14.1% from fiscal 2024. In the quarter to June 2026, revenue grew 15.7%, EPS grew 40.8% and free cash flow fell 52.8%, each against the same quarter a year earlier.
6.00
0.06
−0.99%
Follow LFWD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.98 | 0.51 | 0.36 | 0.47 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.57) | (2.91) | (2.26) | (2.97) | |
P/B ratio |
1.75 | 1.70 | 0.96 | 0.89 | |
Price to Tangible BV |
3.05 | 6.95 | 2.20 | 1.42 | |
EV/Sales |
1.07 | 0.45 | 0.42 | 0.46 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.36) | (0.62) | (0.55) | (0.66) | |
EV/FCF |
(1.36) | (0.62) | (0.55) | (0.65) | |
Quick Ratio |
1.55 | 1.61 | 0.71 | 0.92 | |
Current Ratio |
2.33 | 2.40 | 1.31 | 1.92 | |
Net Debt/EBITDA |
0.25 | 0.95 | (0.08) | 0.72 | |
Debt/Assets |
24.33% | 21.77% | 12.24% | 0.00% | |
Debt/Equity |
0.70 | 1.16 | 0.33 | 0.00 | |
Asset Turnover |
0.71 | 0.67 | 0.83 | 0.71 | |
Operating CF/Net income |
0.52 | 0.34 | 0.66 | 1.21 | |
Capex/Depreciation |
(0.02) | 0.00 | (0.15) | 0.00 | |
Research and Development Expense of Revenue |
26.48% | 148.99% | 16.59% | 11.64% | |
Selling, General and Administrative Expense of Revenue |
77.11% | 148.76% | 105.55% | 82.74% | |
Intangible Assets out of Total Assets |
0.15 | 0.14 | 0.21 | 0.21 | |
Share Based Compensation of Revenue |
3.96% | 4.51% | 3.29% | 2.81% | |
Graham Net Nets |
0.15 | (0.15) | 0.16 | 0.61 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(219.60%) | (296.59%) | (267.14%) | (417.49%) | |
Free Cash Flow Yield |
(79.79%) | (140.66%) | (209.63%) | (152.00%) | |
Revenue per Share |
2.37 | 2.44 | 4.38 | 4.64 | |
Operating CF per Share |
(2.15) | (2.28) | (3.06) | (2.88) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(2.15) | (2.28) | (3.07) | (2.88) | |
Cash per Share |
3.38 | 7.10 | 2.07 | 1.64 | |
Shareholders Equity per Share |
4.37 | 3.91 | 7.24 | 9.56 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.37 | 3.91 | 7.24 | 9.56 | |
Free Cash Flow |
(6.01) | (3.67) | (3.57) | (3.84) | |
Working Capital |
14.79 | 14.92 | 3.77 | 8.29 | |
Capital Expenditures |
(0.01) | — | (0.01) | 0.00 | |
Net Current Asset Value |
3.16 | (1.57) | 1.32 | 6.93 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.86 | 5.41 | 6.07 | 5.98 | |
Average Payables |
6.12 | 5.42 | 5.31 | 5.12 | |
Average Inventory |
6.89 | 6.53 | 6.23 | 7.21 | |
Average Assets |
30.89 | 31.11 | 26.69 | 34.47 | |
Average Common Equity |
13.66 | 12.37 | 13.63 | 23.32 |
Columns are period end dates